Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relacorilant plus nab-paclitaxel showed a PFS benefit in patients with ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

Niraparib approved for all-comers whose tumors responded to chemotherapy Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency. The FDA restricted ...

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, ...

Corcept Therapeutics shares fell 0.9% in premarket trading Monday despite the company reporting late-breaking Phase 3 data ...

Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...

Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...